Pfizer Japan Inc. Obtains Approval For ZYVOX, Detrusitol, J Zoloft In Japan
Published: Apr 24, 2006
Tokyo, Apr 24, 2006 (JCN) - Pfizer Japan announced on April 24 that it received approval for an additional indication for ZYVOX Tablets 600mg/ ZYVOX Injection 600mg, its proprietary antibacterial agent, from the Ministry of Health, Labor and Welfare. ZYVOX is now available for the treatment of infections associated with MRSA (methicillin-resistant Staphylococcus aureus). ZYVOX (linezolid), which has been marketed in Japan since 2001, is currently used in the treatment of infections associated with vancomycin-resistant Enterococcus (VRE).